Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antiretroviral Therapy, Highly Active Clear all
Completed Phase 2 Interventional Results available

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

NCT00267865
View directory record Official record
Conditions
AIDS-Related-Primary Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 30, 2026, 7:41 PM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

NCT00298350
View directory record Official record
Conditions
HIV, HIV-1, Human Immunodeficiency Virus
Interventions
GS-9137 - A Novel HIV-1 Integrase Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional

The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV

NCT00004735
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 30, 2026, 7:41 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

NCT07219862
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active, INDIVIDUALIZED THERAPY, AIDS (Acquired Immune Deficiency Syndrome), Personalized Medicine, Precision Medicine
Interventions
smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources
Other
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

NCT00000895
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate, Nevirapine, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional Results available

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

NCT00491556
View directory record Official record
Conditions
HIV Infections
Interventions
Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

NCT01227044
View directory record Official record
Conditions
Reduction in Heavy Drinking in Patients With HIV
Interventions
Naltrexone, Placebo + Medication Management/Medication Coaching
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 30, 2026, 7:41 PM EDT
Completed No phase listed Observational

Attitudes and Beliefs and the Steps of HIV Care

NCT00749840
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Sep 30, 2026, 7:41 PM EDT
Withdrawn Phase 3 Interventional

Optimal Treatment for Kidney Disease in HIV Infected Adults

NCT00089518
View directory record Official record
Conditions
HIV Infections, Kidney Disease
Interventions
Valsartan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Indianapolis, Indiana • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Increasing HAART-Induced Immune Restoration With Cyclosporine

NCT00031070
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
15
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 30, 2026, 7:41 PM EDT
Terminated Not applicable Interventional

Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

NCT00203853
View directory record Official record
Conditions
HIV Infections
Interventions
pillbox, wristwatch
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

NCT00879047
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Alcohol, Alcohol placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 30, 2026, 7:41 PM EDT
Completed No phase listed Observational

HIV Treatment-Readiness Measure (HTRM) Validation

NCT00686049
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 24 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 30, 2026, 7:41 PM EDT
Not listed Phase 4 Interventional

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

NCT00740064
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Abacavir/Lamivudine
Drug
Lead sponsor
Denver Infectious Disease Consultants, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Denver, Colorado • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

NCT00346697
View directory record Official record
Conditions
HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions
Omega-3 fatty acid administration, Placebo
Drug
Lead sponsor
Brown, Todd, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 30, 2026, 7:41 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection

NCT00001117
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2008 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

NCT01546818
View directory record Official record
Conditions
HIV Infections
Interventions
SAV001-H
Biological
Lead sponsor
Sumagen
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

NCT00050921
View directory record Official record
Conditions
HIV Infections
Interventions
somatropin, Hepatitis A virus, inactivated, Keyhole-Limpet Hemocyanin
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

NCT01625169
View directory record Official record
Conditions
HIV
Interventions
Etravirine pharmacokinetics in breast milk and plasma
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Sep 30, 2026, 7:41 PM EDT